定量[F]FMISO正电子发射断层显像显示，在HER2阳性乳腺癌小鼠模型中，曲妥珠单抗治疗后缺氧情况有所减轻。
Quantitative [F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.
作者信息
Sorace Anna G, Syed Anum K, Barnes Stephanie L, Quarles C Chad, Sanchez Violeta, Kang Hakmook, Yankeelov Thomas E
机构信息
Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, 1912 Speedway, Austin, TX, 78712, USA.
Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
出版信息
Mol Imaging Biol. 2017 Feb;19(1):130-137. doi: 10.1007/s11307-016-0994-1.
Abstract
PURPOSE
Evaluation of [F]fluoromisonidazole ([F]FMISO)-positron emission tomography (PET) imaging as a metric for evaluating early response to trastuzumab therapy with histological validation in a murine model of HER2+ breast cancer.
PROCEDURES
Mice with BT474, HER2+ tumors, were imaged with [F]FMISO-PET during trastuzumab therapy. Pimonidazole staining was used to confirm hypoxia from imaging.
RESULTS
[F]FMISO-PET indicated significant decreases in hypoxia beginning on day 3 (P < 0.01) prior to changes in tumor size. These results were confirmed with pimonidazole staining on day 7 (P < 0.01); additionally, there was a significant positive linear correlation between histology and PET imaging (r = 0.85).
CONCLUSIONS
[F]FMISO-PET is a clinically relevant modality which provides the opportunity to (1) predict response to HER2+ therapy before changes in tumor size and (2) identify decreases in hypoxia which has the potential to guide subsequent therapy.
摘要
目的
在HER2阳性乳腺癌小鼠模型中，评估[F]氟米索硝唑（[F]FMISO）正电子发射断层扫描（PET）成像作为评估曲妥珠单抗治疗早期反应并进行组织学验证的指标。
程序
对患有BT474 HER2阳性肿瘤的小鼠在曲妥珠单抗治疗期间进行[F]FMISO-PET成像。使用匹莫硝唑染色来确认成像中的缺氧情况。
结果
[F]FMISO-PET显示，在肿瘤大小改变之前，从第3天开始缺氧情况显著降低（P < 0.01）。这些结果在第7天通过匹莫硝唑染色得到证实（P < 0.01）；此外，组织学与PET成像之间存在显著的正线性相关性（r = 0.85）。
结论
[F]FMISO-PET是一种具有临床相关性的检查方法，它提供了以下机会：（1）在肿瘤大小改变之前预测对HER2阳性治疗的反应；（2）识别缺氧情况的降低，这有可能指导后续治疗。
相似文献
1
Quantitative [F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.定量[F]FMISO正电子发射断层显像显示，在HER2阳性乳腺癌小鼠模型中，曲妥珠单抗治疗后缺氧情况有所减轻。
Mol Imaging Biol. 2017 Feb;19(1):130-137. doi: 10.1007/s11307-016-0994-1.
2
F-HX4/F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice.基于 F-HX4/F-FMISO 的微 PET 用于成像小鼠肿瘤缺氧和放疗相关变化。
Biomed Pharmacother. 2019 Nov;119:109454. doi: 10.1016/j.biopha.2019.109454. Epub 2019 Sep 14.
3
Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer.定量成像和免疫组化分析曲妥珠单抗诱导的 HER2+乳腺癌肿瘤内异质性改变。
Neoplasia. 2019 Jan;21(1):17-29. doi: 10.1016/j.neo.2018.10.008. Epub 2018 Nov 23.
4
The Effects of Pulsed Radiation Therapy on Tumor Oxygenation in 2 Murine Models of Head and Neck Squamous Cell Carcinoma.脉冲辐射治疗对头颈部鳞状细胞癌 2 种小鼠模型肿瘤氧合作用的影响。
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):820-8. doi: 10.1016/j.ijrobp.2015.04.002. Epub 2015 Apr 12.
5
Comparative evaluation of [F]DiFA and its analogs as novel hypoxia positron emission tomography and [F]FMISO as the standard.新型正电子发射断层扫描用[F]DiFA 及其类似物与[F]FMISO 作为标准的比较评估。
Nucl Med Biol. 2019 Mar;70:39-45. doi: 10.1016/j.nucmedbio.2019.01.008. Epub 2019 Feb 8.
6
Quantitative Analysis of [F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry.用于肿瘤缺氧的[F]FMISO正电子发射断层显像的定量分析：建模结果与免疫组织化学的相关性
Mol Imaging Biol. 2017 Feb;19(1):120-129. doi: 10.1007/s11307-016-0975-4.
7
Correlation of Tumor Hypoxia Metrics Derived from F-Fluoromisonidazole Positron Emission Tomography and Pimonidazole Fluorescence Images of Optically Cleared Brain Tissue.基于 F-氟代莫司他正电子发射断层扫描和光透明脑组织中吡莫硝唑荧光图像的肿瘤乏氧指标相关性。
Tomography. 2020 Dec;6(4):379-388. doi: 10.18383/j.tom.2020.00046.
8
F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy.用于表征抗血管生成治疗反应中肿瘤灌注和缺氧的F-氟米索硝唑动力学建模
J Nucl Med. 2017 Oct;58(10):1567-1573. doi: 10.2967/jnumed.117.190892. Epub 2017 Mar 30.
9
Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [F]FMISO.使用 pimonidazole 和 [F]FMISO 评估抗 PD-1 治疗对肿瘤缺氧的缓解作用。
Nucl Med Biol. 2022 May-Jun;108-109:85-92. doi: 10.1016/j.nucmedbio.2022.03.005. Epub 2022 Mar 24.
10
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.在免疫活性的管腔B（HER2阳性）型乳腺癌模型中使用[（18）F]FDG和[（18）F]FMISO PET监测舒尼替尼的治疗效果。
BMC Cancer. 2015 Jul 22;15:534. doi: 10.1186/s12885-015-1540-2.
引用本文的文献
1
Multiparametric Analysis of PET and Quantitative MRI for Identifying Intratumoral Habitats and Characterizing Trastuzumab-Induced Alterations.PET与定量MRI的多参数分析用于识别瘤内微环境并表征曲妥珠单抗诱导的改变。
Cancers (Basel). 2025 Jul 22;17(15):2422. doi: 10.3390/cancers17152422.
2
Affinity of PET-MRI Tracers for Hypoxic Cells in Breast Cancer: A Systematic Review.乳腺癌中 PET-MRI 示踪剂与乏氧细胞的亲和力：系统评价。
Cells. 2024 Jun 17;13(12):1048. doi: 10.3390/cells13121048.
3
[F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response.FMISO-PET 成像揭示了缺氧严重程度在检查点阻断反应中的作用。
Nucl Med Biol. 2024 Jul-Aug;134-135:108918. doi: 10.1016/j.nucmedbio.2024.108918. Epub 2024 May 8.
4
Assessment of tumor hypoxia in spontaneous canine tumors after treatment with OMX, a novel H-NOX oxygen carrier, with [F]FMISO PET/CT.评估新型 H-NOX 氧载体 OMX 治疗后自发性犬肿瘤的肿瘤缺氧情况，结合 [F]FMISO PET/CT。
BMC Vet Res. 2024 May 13;20(1):196. doi: 10.1186/s12917-024-04061-4.
5
Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC.双重抗 HER2/EGFR 抑制协同增强治疗效果并改变头颈部鳞状细胞癌的肿瘤氧合作用。
Sci Rep. 2024 Feb 14;14(1):3771. doi: 10.1038/s41598-024-52897-5.
6
Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy.采用逐步数学建模策略研究临床前免疫治疗实验中的肿瘤-宿主反应动态。
Math Biosci. 2023 Dec;366:109106. doi: 10.1016/j.mbs.2023.109106. Epub 2023 Nov 4.
7
Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis.代谢重编程在癌症成像和诊断中的应用。
Int J Mol Sci. 2022 Dec 13;23(24):15831. doi: 10.3390/ijms232415831.
8
Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.量化曲妥珠单抗与放射治疗联合应用对人表皮生长因子受体2阳性乳腺癌的影响
Cancers (Basel). 2022 Aug 31;14(17):4234. doi: 10.3390/cancers14174234.
9
Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer.通过MRI栖息地量化肿瘤异质性以表征HER2+乳腺癌中的微环境改变
Cancers (Basel). 2022 Apr 6;14(7):1837. doi: 10.3390/cancers14071837.
10
Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer.颗粒酶B的临床前PET成像显示，在三阴性乳腺癌中，紫杉醇与免疫检查点抑制联合使用后免疫反应得到增强。
Pharmaceutics. 2022 Feb 18;14(2):440. doi: 10.3390/pharmaceutics14020440.
本文引用的文献
1
Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.曲妥珠单抗改善HER2阳性乳腺癌小鼠模型中肿瘤灌注及细胞毒性治疗的血管递送：初步结果
Breast Cancer Res Treat. 2016 Jan;155(2):273-84. doi: 10.1007/s10549-016-3680-8. Epub 2016 Jan 20.
2
The accumulation mechanism of the hypoxia imaging probe "FMISO" by imaging mass spectrometry: possible involvement of low-molecular metabolites.成像质谱法对缺氧成像探针“FMISO”的蓄积机制：低分子代谢物的可能参与
Sci Rep. 2015 Nov 19;5:16802. doi: 10.1038/srep16802.
3
Dynamic contrast enhanced ultrasound for therapy monitoring.用于治疗监测的动态对比增强超声
Eur J Radiol. 2015 Sep;84(9):1650-7. doi: 10.1016/j.ejrad.2015.05.013. Epub 2015 Jun 28.
4
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.在免疫活性的管腔B（HER2阳性）型乳腺癌模型中使用[（18）F]FDG和[（18）F]FMISO PET监测舒尼替尼的治疗效果。
BMC Cancer. 2015 Jul 22;15:534. doi: 10.1186/s12885-015-1540-2.
5
18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.使用图像衍生的血液替代组织参考区域对人类癌症患者的缺氧情况进行18F-氟米索硝唑定量分析。
J Nucl Med. 2015 Aug;56(8):1223-8. doi: 10.2967/jnumed.115.158717. Epub 2015 Jun 25.
6
Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.EGFR突变型非小细胞肺癌靶向治疗后的肿瘤缺氧反应：FMISO-PET的概念验证
Technol Cancer Res Treat. 2016 Apr;15(2):234-42. doi: 10.1177/1533034615574386. Epub 2015 Mar 10.
7
F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.用于肿瘤缺氧成像的F-18氟米索硝唑：为个性化癌症治疗对微环境进行成像
Semin Nucl Med. 2015 Mar;45(2):151-62. doi: 10.1053/j.semnuclmed.2014.10.006.
8
Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.多参数磁共振成像预测乳腺癌新辅助化疗第一周期后的病理反应
Invest Radiol. 2015 Apr;50(4):195-204. doi: 10.1097/RLI.0000000000000100.
9
Quantitative multimodality imaging in cancer research and therapy.癌症研究与治疗中的定量多模态成像
Nat Rev Clin Oncol. 2014 Nov;11(11):670-80. doi: 10.1038/nrclinonc.2014.134. Epub 2014 Aug 12.
10
The meaning, measurement and modification of hypoxia in the laboratory and the clinic.实验室及临床环境下低氧的含义、测量与改善
Clin Oncol (R Coll Radiol). 2014 May;26(5):277-88. doi: 10.1016/j.clon.2014.02.002. Epub 2014 Mar 3.
Zotero 插件